RNA Analysis/ Transcriptomics Global Market Report 2024

Transcriptomics, also known as RNA analysis, is the study of the transcriptome under specific circumstances, environmental conditions, or within specific cells using high-throughput methods.

The main product categories in the RNA analysis/transcriptomics market include reagents/consumables, instruments, and software. These products find applications in various fields, such as clinical diagnostics, drug discovery, toxicogenomics, comparative transcriptomics, and RNA interference. The major technologies involved in RNA analysis/transcriptomics are microarrays, sequencing, polymerase chain reaction, and RNA interference. In clinical diagnostics, RNA analysis is employed to detect different RNA species, pathogen RNA, splice variants, and other elements crucial for disease diagnosis.

The RNA analysis/ transcriptomics market research report is one of a series of new reports that provides RNA analysis/ transcriptomics market statistics, including RNA analysis/ transcriptomics industry global market size, regional shares, competitors with a RNA analysis/ transcriptomics market share, detailed RNA analysis/ transcriptomics market segments, market trends and opportunities, and any further data you may need to thrive in the RNA analysis/ transcriptomics industry. This RNA analysis/ transcriptomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rna analysis/ transcriptomics market size has grown rapidly in recent years. It will grow from $6.89 billion in 2023 to $7.91 billion in 2024 at a compound annual growth rate (CAGR) of 14.9%. The growth observed in the historic period can be attributed to various factors, including advancements in cancer research and precision medicine, increased focus on drug discovery and development, applications in infectious disease diagnostics, the emergence of personalized medicine approaches, substantial funding from academic and government sources, and the expanding applications of transcriptomics in agriculture.

The rna analysis/ transcriptomics market size is expected to see rapid growth in the next few years. It will grow to $14.2 billion in 2028 at a compound annual growth rate (CAGR) of 15.7%. The anticipated growth in the forecast period can be attributed to various factors, including the increasing applications of single-cell RNA sequencing, the integration of RNA analysis in clinical diagnostics, the development of RNA-based therapies and vaccines, advancements in bioinformatics and data analysis tools, and the ongoing research in biomarker discovery and validation. Additionally, major trends expected in the forecast period include the rise of spatial transcriptomics and in situ RNA analysis, the adoption of long-read RNA sequencing technologies, analysis of RNA editing and modifications, integration of artificial intelligence in RNA data analysis, the exploration of RNA therapeutics for rare diseases, and the use of RNA-based liquid biopsy for cancer detection.

The growth of the RNA analysis/transcriptomics market is anticipated to be driven by the increasing demand for personalized medicine. Personalized medicine involves tailoring medical treatment to the unique characteristics of each patient. The RNA-Seq technology is well-suited to manage the substantial clinical workload associated with implementing personalized clinical care practices and processes. The Personalized Medicine Coalition (PMC) reported in October 2022 that there will be over 75,000 genetic testing products and 300 personalized medicines available for various conditions such as multiple types of cancer, genetic rare diseases, and chronic and infectious diseases. This surge in demand for personalized medicines is a key factor propelling the growth of the RNA analysis market.

The growth of the RNA analysis/transcriptomics market is expected to be fueled by the increasing prevalence of chronic diseases. Chronic diseases are long-lasting conditions that significantly impact daily activities, necessitate ongoing medical care, or both. RNA analysis and transcriptomics play a crucial role in chronic disease research, offering a deeper understanding of disease mechanisms, improved diagnostics, and the development of more targeted and personalized therapeutic interventions. According to the World Health Organization, non-communicable diseases (NCDs) or chronic diseases account for 74% of the 41 million global deaths annually. This includes deaths from cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes. The rising incidence of chronic diseases is a major driver for the growth of the RNA analysis/transcriptomics market.

An emerging trend in the RNA analysis/transcriptomics market is the focus on technological advancements and innovations in RNA analysis. Next-generation sequencing (NGS) and RNA interference (RNAi) are among the technologies contributing to improved precision and accuracy in analyzing transcriptional activity. Illumina's development of Next-generation sequencing, for example, has proven successful in fragmenting DNA/RNA, sequencing libraries, and reassembling them, enhancing genomic sequence analysis.

Major companies in the RNA analysis/transcriptomics market are increasingly emphasizing the introduction of innovative portfolios to gain a competitive advantage. Twist Bioscience Corporation, in May 2023, launched a comprehensive RNA sequencing tools portfolio, including specific target enrichment capabilities for RNA and whole transcriptome sequencing. The portfolio comprises products such as the Twist RNA Exome, Twist RNA Library Prep Kit, and Twist Ribosomal RNA (rRNA) and Hemoglobin (Globin) Depletion Kit, offering complete workflows for analyzing mRNA protein coding sequences, custom targets, and total RNA.

Strategic partnerships and collaborations are a significant focus for major companies in the RNA analysis/transcriptomics market. These partnerships often involve integrating expertise in RNA library preparation kits, combining the knowledge and resources of different organizations. For instance, Singular Genomics Systems Inc. collaborated with Lexogen in January 2022 to demonstrate the compatibility of the G4 sequencing platform with Lexogen's products for RNA research. This partnership aims to provide customers with a seamless integration of the G4 into existing Next-Generation Sequencing (NGS) workflows.

Major companies operating in the rna analysis/ transcriptomics market include Affymetrix Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., GE Healthcare, Illumina Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., Fluidigm Corporation, Promega Corporation, bioMérieux S.A., CD Genomics Inc., Eurofins Scientific SE, Merck KGaA, Pacific Biosciences of California Inc., Danaher Corporation, Genewiz Inc., Oxford Nanopore Technologies Ltd., BGI Group, Genotypic Technology Pvt. Ltd., MedGenome Labs Pvt. Ltd., Xcelris Labs Ltd., Ocimum Biosolutions Ltd., Strand Life Sciences Pvt. Ltd., SciGenom Labs Pvt. Ltd., Oncocyte Corporation, Tempus Labs Inc., ArcherDX Inc., HTG Molecular Diagnostics Inc.

North America was the largest region in the RNA analysis/transcriptomics market in 2023. This region is expected to be the fastest-growing region in the forecast period. The regions covered in the RNA analysis/ transcriptomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the RNA analysis/ transcriptomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The RNA analysis/ transcriptomics market includes revenues earned by entities by providing services such as Whole-Genome Sequencing, Whole-Exome Sequencing, Targeted Sequencing, Microarray Analysis, Sanger Sequencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.